{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"27"}],"units":"Participants"}],"description":"To determine the prevalence of NFKB2 rearrangement according to the type of previous therapies received in all patients screened in the study.","groups":[{"description":"MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO","id":"OG000","title":"Arm B (Ixazomib and Dexamethasone)"},{"description":"MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO\n\nLenalidomide: Given PO","id":"OG001","title":"Arm C (Ixazomib, Dexamethasone, Lenalidomide)"},{"description":"UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO","id":"OG002","title":"Arm A (Ixazomib and Dexamethasone)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At baseline and month 12","title":"Prevalence of NFKB2 Rearrangement in Relapsed/Refractory Multiple Myeloma Patients Screened in the Study.","type":"SECONDARY","unitOfMeasure":"Participants"}